Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Selectis Health (GBCS) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Selectis Health (GBCS) over the last 7 years, with Q3 2025 value amounting to $106763.0.

  • Selectis Health's Asset Writedowns and Impairment fell 8735.68% to $106763.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $340752.0, marking a year-over-year decrease of 8694.68%. This contributed to the annual value of $1.0 million for FY2024, which is 6185.01% down from last year.
  • Latest data reveals that Selectis Health reported Asset Writedowns and Impairment of $106763.0 as of Q3 2025, which was down 8735.68% from $136348.0 recorded in Q2 2025.
  • Selectis Health's Asset Writedowns and Impairment's 5-year high stood at $1.6 million during Q4 2023, with a 5-year trough of -$8001.0 in Q2 2021.
  • For the 5-year period, Selectis Health's Asset Writedowns and Impairment averaged around $335813.9, with its median value being $252050.0 (2022).
  • Per our database at Business Quant, Selectis Health's Asset Writedowns and Impairment tumbled by 11396.77% in 2021 and then soared by 356845.39% in 2022.
  • Quarter analysis of 5 years shows Selectis Health's Asset Writedowns and Impairment stood at $869263.0 in 2021, then plummeted by 33.18% to $580830.0 in 2022, then soared by 169.58% to $1.6 million in 2023, then plummeted by 100.13% to -$1967.0 in 2024, then surged by 5527.71% to $106763.0 in 2025.
  • Its Asset Writedowns and Impairment was $106763.0 in Q3 2025, compared to $136348.0 in Q2 2025 and $99608.0 in Q1 2025.